Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma.

In line with known prognostic factors in patients treated with TCEs, comparison of baseline clinical characteristics between responders and nonresponders showed a trend toward higher representation of patients with high-risk features and a significantly higher median age and shorter time from last therapy in nonresponders ( supplemental Table 1 ).

also in 53,322 other papers

We observed a treatment-induced, significant decrease in CD8 T-cell fractions and a trend toward significance in the decrease of CD4 T-cell fractions, together with a significant increase in natural killer cell fractions in patients with CMR.

also in 3,729 other papers